PPD announced it will provide drug development services to advance Pfizer’s portfolio.
PPD announced on August 3, 2020 that it has signed a three-year agreement with Pfizer to provide drug development services to advance Pfizer’s portfolio. Financial details of the deal were not disclosed.
According to a PPD press release, the new agreement will coincide with the companies’ current relationship in which PPD provides development and laboratory services to Pfizer’s drug development initiatives across multiple therapeutic areas.
“United in purpose, we are committed to building on our long-standing relationship with Pfizer with innovative solutions, quality execution, and the dedication of our talented teams to help Pfizer deliver exciting new therapies,” said David Simmons, PPD’s chairman and CEO, in the press release. “PPD is strategically positioned to continue supporting Pfizer in its pursuit of breakthroughs that change patients’ lives. We are privileged to take the next steps together and contribute to Pfizer’s initiatives to achieve a healthier world.”
Source: PPD
Diving Deep into Carrier-Based Formulation and Process Optimization
December 23rd 2024Carrier-based formulations for dry powder inhalers are carefully designed to transport extremely small particles into the lungs. Jet milling can be used to micronize these particles, with both high and low shear mixing processes used to formulate mixtures capable of carrying the fine API particles into the deep lung. This paper looks at the requirements for pulmonary delivery via carrier-based inhaled powder formulations, and how jet milling can be used to manufacture effective and stable materials for these formulations
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.